AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00954421 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: Use of two ipsilateral thalamic Deep Brain Stimulation electrodes (one at the ventralis intermedius nucleus/ventralis oralis posterior nucleus border or VIM and one at the ventralis oralis anterior nucleus/ventralis oralis posterior nucleus border or VO) for treatment of disabling and medication refractory tremor secondary to head trauma or multiple sclerosis.
Study NCT04508322 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HGA
Description: Headgear Activator
Study NCT04508322 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FA
Description: Fixed Orthodontic Appliance
Study NCT04382274 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadratus Lumborum Block
Description: transducer will be placed at the level of the anterior superior iliac spine and moved cranially until the three abdominal wall muscles will be clearly identified. The external oblique muscle will be followed posterolaterally until its posterior border will be visualized leaving underneath the internal oblique muscle, like a roof over the QL muscle. The probe will be tilted down to identify a bright hyperechoic line that represented the middle layer of the thoracolumbar fascia. The needle will be inserted in plane from anterolateral to posteromedial. The needle tip will be placed between the thoracolumbar fascia and the QL muscle, and after negative aspiration, the correct position of the needle will be proved by injection of 5 mL of normal saline to confirm the space with a hypoechoic image and hydrodissection. An injection of 20 mL of 0.25% bupivacaine will be applied
Study NCT04382274 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dual Transversus Abdominis Plane and Ilioinguinal/Iliohypogastric Nerve blocks
Description: the probe will be located between the iliac crest and the lower costal margin in the anterior axillary line at the level of umbilicus, and the layers of abdominal wall will be identified (external oblique, internal oblique, and transverse abdominis muscles). In-plane technique will be used and the tip of the needle was inserted between the internal oblique and transverse abdominis muscles. After negative aspiration (to exclude intravascular injection), 20 mL of 0.25% bupivacaine will be injected. Then abdomen will be scanned through anterior superior iliac spine (ASIS)-umbilicus line. Ilioinguinal nerve can be visualised between the internal oblique and transverse or external oblique muscles and within 1 to 3 cm from the ASIS. The iliohypogastric nerve lies immediately adjacent. After negative aspiration (to exclude intravascular injection), 10 mL of 0.25% bupivacaine will be injected. The same technique will be performed on the other side.
Study NCT01262703 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReZolve Stent
Description: ReZolve Sirolimus-Eluting Bioresorbable Coronary Stent
Study NCT03270423 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PathMate2
Description: To improve self-regulation of overweight adolescents and subsequently their weight status, we tested, whether a biofeedback relaxation exercise decreases stress and whether relaxation services as well as sensor data integration implemented in a novel Smartphone App supported intervention have effects on stress, physical activity and weight outcomes. During the intensive phase of 6 months, patients of the intervention group (IG) are equipped with a smartphone and a specially designed chat App with game character, which encourages them through a virtual coach to achieve daily activity, healty lifestyle or relaxation challenges and earn virtual rewards, to increase adherance to the health information system.
Study NCT03270423 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PathMateS
Description: Overweight or obese adolescents of the treatment as-usual group (CG) have monthly visits on site during the intensive phase. Counseling for physical activity, healthy eating and lifestyle as well as psychosocial wellbeing is provided by a pediatrician.
Study NCT02180022 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After randomization, placebo was treated for 12 weeks
Study NCT02180022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onion peel extract
Description: After randomization, onion peel extract was treated for 12 weeks
Study NCT04046718 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electro-acupuncture stimulation
Description: stimulation of acupoints of the liver meridian of lv3 lv14
Study NCT02159560 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural catheter
Description: The intervention is the use of an end-holed epidural catheter or three-holed side port epidural catheter
Study NCT02902003 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Empowering Families
Description: A program that integrates the healthy relationship curriculum, Family Wellness, into a comprehensive set of services that includes case management, employment services, and financial coaching. The program will have four core components: (1) 20 hours of core workshop sessions using the Family Wellness curriculum; (2) case management; (3) employment services; and (4) financial coaching. The core component of Empowering Families will be a 20-hour group workshop, organized into eight two-and-a-half-hour weekly sessions (Table 1). The main content of these sessions will be based on the Family Wellness relationship education curriculum which will be covered in six sessions. These six sessions will be led by two trained facilitators employed by The Parenting Center. The core workshops will be supplemented with two additional sessions on financial planning and employment topics that will designed to be useful to all participants, regardless of their level of financial and employment needs.
Study NCT02762253 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Riboflavin drops
Description: Riboflavin drops were used every 2 minutes for 30 minutes on the cornea then exposed to 5 minutes of Ultraviolet light at an intensity of 18mW/cm2
Study NCT00763867 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00763867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Study NCT03565120 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Aggressive Thoracic Radiotherapy
Description: The target of the radiotherapy includes primary tumor and the locoregional positive lymph nodes, with a dose(BED)≥53Gray(Gy)
Study NCT03252275 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer learning
Description: Peer learning plus HBB and ECEB
Study NCT00617188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant, 500 milligrams (mg) intramuscularly (IM) on Day 1, 250 mg IM on Day 15, and 250 mg IM on Day 29 and every 28 days thereafter until either intolerance or disease progression.
Study NCT02882087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo plus MTX
Description: All patients had a foundation MTX therapy.The researchers evaluated the efficacy of the patient in 12 week.study investigator evaluate the patients of curative effect . The researchers evaluated the efficacy of the patient in 12 week.Evaluation of efficacy in patients if not get the ACR20 response, adjust the treatment plan given the test drug.Test group continue to the test drug,placebo group switch to the test drug.
Study NCT02882087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC18 160 mg plus MTX
Study NCT00591045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX
Description: oxaliplatin 100mg/m2, CF 400mg/m2, 5-FU 2400 mg/m2 46hr civ
Study NCT03819738 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: fMRI
Description: Functional MRI will be performed in 1 scan, which will take 1.5 h. (scanning time = 30 min)
Study NCT02307760 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Human Milk Fortifier A
Description: Acidified concentrated liquid human milk fortifier
Study NCT02307760 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Human Milk Fortifier B
Description: Non-acidified concentrated liquid human milk fortifier
Study NCT04051827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam Oral Solution and Midazolam Intravenous Infusion.
Study NCT04051827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-788
Description: TAK-788 Oral Capsules.
Study NCT04513704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Semaglutide
Description: Participants will receive oral semaglutide tablet once daily for 10 days (3 mg for first 5 days and 7 mg for the next 5 days).
Study NCT04513704 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Semaglutide
Description: Participants will receive oral semaglutide tablet once daily for 10 days (3 mg for first 5 days and 7 mg for the next 5 days).
Study NCT03331016 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart to Heart Training
Description: Training for foster and kinship caregivers on sexual health and how to effectively communicate with and monitor youth in their care, with the aim of reducing unintended pregnancies and sexually transmitted infections in this youth population.
Study NCT03331016 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Heart to Heart Training
Description: Training for foster and kinship caregivers on sexual health and how to effectively communicate with and monitor youth in their care, with the aim of reducing unintended pregnancies and sexually transmitted infections in this youth population.
Study NCT04326127 — intervention group
Intervention type: DEVICE
Intervention: Intervention is the validation of a sleep monitoring device (i.e. Somfit) against the gold-standard polysomnograph with electroencephalograph (i.e. the Greal system)
Description: Data were recorded overnight by both devices simultaneously
Study NCT03237182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Individualized TB treatment with multiple drugs
Description: Patients with drug-resistant TB will receive a combination of any of the following drugs based on whole genome sequencing:~rifampicin, rifabutin, isoniazid, high dose isoniazid, pyrazinamide, ethambutol, levofloxacin, moxifloxacin, ofloxacin, gatifloxacin, amikacin, capreomycin, kanamycin, streptomycin, ethionamide, prothionamide, cycloserine, terizidone, pretomanid, linezolid, sutezolid, clofazimine, bedaquiline, delaminid, para-aminosalicylic acid, imipenem/cilastatin, meropenem, amoxicillin/clavulanate, clarithromycin, azithromycin and thioacetazone
Study NCT03237182 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standardized TB treatment with multiple drugs
Description: Patients with drug-resistant TB with receive a combination of any of the following drugs based on South African Department of Health guidelines:~rifampicin, rifabutin, isoniazid, high dose isoniazid, pyrazinamide, ethambutol, levofloxacin, moxifloxacin, ofloxacin, gatifloxacin, amikacin, capreomycin, kanamycin, streptomycin, ethionamide, prothionamide, cycloserine, terizidone, pretomanid, linezolid, sutezolid, clofazimine, bedaquiline, delaminid, para-aminosalicylic acid, imipenem/cilastatin, meropenem, amoxicillin/clavulanate, clarithromycin, azithromycin and thioacetazone
Study NCT04121494 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChadOx1 85A - aerosol
Description: Aerosol administration through the Omron MicroAIR NE-U22 nebuliser
Study NCT04121494 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChadOx1 85A - IM
Description: Intramuscular administration
Study NCT02778256 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vestibular stimulation
Description: A specific vestibular stimulation technique is applied to the experimental group
Study NCT02778256 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham vestibular stimulation
Description: Sham vestibular stimulation using lower than threshold stimuli. The absence of vestibular nystagmus confirms that it is sham.
Study NCT00690040 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley catheter
Description: Single balloon catheter
Study NCT00690040 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Atad catheter
Description: Double balloon catheter
Study NCT00825617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy
Description: Women with TS were treated with oral hormone substitution consisting of 2 mg 17β-estradiol/day for days 1-12, 2 mg 17β-estradiol/day and 1 mg norethisterone acetate/day for days 13-22 and 1 mg 17β-estradiol/day for days 23-28 (Trisekvens, Novo Nordisk A/S, Bagsværd, Denmark)
Study NCT00001962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclizumab
Description: Daclizumab, 1mg/kg, every 2 weeks for a total of 5 infusions.
Study NCT01882751 — intervention group
Intervention type: DEVICE
Intervention: Conformis CR Total Knee Replacement
Description: iTotal CR by Conformis
Study NCT01882751 — intervention group
Intervention type: DEVICE
Intervention: Off the Shelf
Description: A standard knee replacement not using ConforMIS' iFit technology
Study NCT04448509 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Peripheral blood mononuclear cell apheresis
Description: Peripheral blood mononuclear cell collection for tumor immunotherapy study of UCAR-T cells
Study NCT04536987 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HEXORR
Description: The subject receives robotic assistance from the HEXORR robot during finger and thumb movements. Several different video games are used to provide feedback of performance and motivate the training. The assistance level is adjusted automatically in some games and manually in other games to enable a target success rate of 67% when playing the games.
Study NCT02133053 — intervention group
Intervention type: OTHER
Intervention: Medical Device, drug-like
Description: Ectoin Allergy Nasal Spray
Study NCT02133053 — intervention group
Intervention type: DRUG
Intervention: Beclomethasone
Description: Beclomethasone nasal spray
Study NCT02787525 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: A clinical sweep follow up will be performed in all patients of both groups and results will be analyzed. It will be in form of a standardized questionnaire and if necessary telephone interviews asking about thrombo-embolic events, stroke, death, any bleeding but also on their current medication, comorbidities (i.e. arterial hypertension, diabetes mellitus, renal impairment and liver disease), any hospitalizations and their quality of life. For all events, the source documents will be gathered from general physicians, cardiologists, hospitals or registry offices.~The questionnaire will be sent by mail to the patients. If information is missing or unclear, patients and if necessary their treating physician will be contacted by phone.
Study NCT00873353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine + erlotinib
Description: 6 cycles (3 weeks each one) of :~* capecitabine 1000mg/m2, bid, oral. Days: 1-14 every three weeks~* erlotinib (Tarceva®) 150mg/day, oral. Days: every days
Study NCT02725957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trehalose for IV Infusion
Study NCT02725957 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline 0.9% IV
Study NCT04058613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALB Protein, Human
Description: Albumin infusions will be given at a dose of 40 g twice weekly till a steady albumin level of 4.0g/dl is reached followed by 100ml of 20% albumin at least once in two weeks to maintain a steady albumin level of 4.0g/dl along with the standard medical therapy
Study NCT04058613 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT02673151 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT) scan
Description: PET/CT scan using 68gallium-labeled prostate-specific membrane antigen-11 (68-Ga-PSMA-11).
Study NCT02673151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-11
Description: 68gallium-labeled prostate-specific membrane antigen-11 (68-Ga-PSMA-11), administered by intravenous (IV) injection.
Study NCT02673151 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)
Description: PET/CT scan using 68gallium-labeled prostate-specific membrane antigen-11 (68-Ga-PSMA-11).
Study NCT04023721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inarigivir soproxil
Description: Inarigivir soproxil 200 mg tablets
Study NCT04023721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nucleoside/nucleotide (NUC) analogue inhibitors
Description: Continuation of prestudy NUC therapy
Study NCT02745262 — intervention group
Intervention type: OTHER
Intervention: Collect retrospectively the follow-up data
Description: Collect retrospectively the follow-up data. Each patient is called in order to request data authorization, to complete and track information.
Study NCT01894373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adoptive Immunotherapy
Description: Biological: in vitro expanded Cytokine Induced Killer (CIK) cells Procedure: Infusion of autologous CIK cells
Study NCT01894373 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CIK
Study NCT02647320 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin 100 mg
Description: Two sitagliptin 50 mg tablets, over-encapsulated to provide a once-daily dose of 100 mg, for oral administration
Study NCT02647320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-8500a 25mg
Description: DS-8500a 25mg tablet for oral administration
Study NCT02647320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Tablet
Description: Placebo matching DS-8500a tablet for oral administration
Study NCT02647320 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablet
Description: Placebo matching DS-8500a tablet for oral administration
Study NCT02647320 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Tablet
Description: Placebo matching DS-8500a tablet for oral administration
Study NCT02647320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Capsule
Description: Placebo matching sitagliptin over-capsule for oral administration
Study NCT02647320 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsule
Description: Placebo matching sitagliptin over-capsule for oral administration
Study NCT02049151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tecemotide
Description: Tecemotide injection will be administered once weekly subcutaneously at a dose of 806 microgram up to Week 8 and from Week 14, every 6 weeks until end-of-trial, or until NSCLC progression.
Study NCT02049151 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo injection will be administered once weekly subcutaneously up to Week 8 and from Week 14, every 6 weeks until end-of-trial, or until NSCLC progression.
Study NCT02049151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CPA)
Description: CPA injection will be administered as a single intravenous infusion at a dose of 300 milligram per square meter (mg/m\^2) (to a maximum of 600 mg) 3 days before the first injection of tecemotide.
Study NCT02049151 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline (sodium chloride)
Description: Matching placebo (saline) injection will be administered as a single intravenous (0.9 percent \[%\] sodium chloride) infusion 3 days before the first injection of tecemotide-matching placebo.
Study NCT00128076 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: All-Arthroscopic repair
Description: joint techniques and repair are both performed entirely through the arthroscope
Study NCT00128076 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mini-open repair
Description: repair is performed though a small incision and the arthroscope can be used to address problems within the joint (as per traditional diagnostic procedures)
Study NCT00107120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Escitalopram 10mg per day for three weeks, 10-20mg per day for up to the remaining 5 weeks
Study NCT00107120 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily for up to 8 weeks
Study NCT02203123 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrasound
Study NCT02203123 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: normal saline
Study NCT03368911 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oral/Nasal Endotracheal Tube, Reinforced (Covidien)
Description: Use Oral/Nasal Endotracheal Tube, Reinforced (Covidien) for endotracheal intubation
Study NCT03368911 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TaperGuard oral tracheal tube (Covidien)
Description: Use TaperGuard oral tracheal tube (Covidien) for endotracheal intubation
Study NCT00344474 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRE-Venture: Personality Risk Education
Description: Motivational and Cognitive-Behavioural interventions targeting four personality risk factors for substance misuse. Two, 90-minute group sessions conducted at school with personality-matched peers and trained psychologists/councellors and co-facilitators.
Study NCT03442985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palovarotene 2.5 mg
Description: Subjects received a weight-adjusted dose equivalent of 2.5 mg palovarotene, once daily, for up to 24 months.